- Home
- LPCN vs XAIR Comparison
LPCN vs XAIR Comparison
Compare LPCN & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- XAIR
- Stock Information
- Founded
- LPCN 1997
- XAIR 2011
- Country
- LPCN United States
- XAIR United States
- Employees
- LPCN N/A
- XAIR N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- LPCN Health Care
- XAIR Health Care
- Exchange
- LPCN Nasdaq
- XAIR Nasdaq
- Market Cap
- LPCN 16.1M
- XAIR 17.0M
- IPO Year
- LPCN N/A
- XAIR N/A
- Fundamental
- Price
- LPCN $2.89
- XAIR $2.21
- Analyst Decision
- LPCN Strong Buy
- XAIR Strong Buy
- Analyst Count
- LPCN 2
- XAIR 1
- Target Price
- LPCN $9.00
- XAIR $11.00
- AVG Volume (30 Days)
- LPCN 16.1K
- XAIR 186.7K
- Earning Date
- LPCN 11-06-2025
- XAIR 08-12-2025
- Dividend Yield
- LPCN N/A
- XAIR N/A
- EPS Growth
- LPCN N/A
- XAIR N/A
- EPS
- LPCN N/A
- XAIR N/A
- Revenue
- LPCN $4,208,119.00
- XAIR $4,782,000.00
- Revenue This Year
- LPCN N/A
- XAIR $265.24
- Revenue Next Year
- LPCN N/A
- XAIR $136.17
- P/E Ratio
- LPCN N/A
- XAIR N/A
- Revenue Growth
- LPCN N/A
- XAIR 168.20
- 52 Week Low
- LPCN $2.68
- XAIR $2.02
- 52 Week High
- LPCN $6.17
- XAIR $13.52
- Technical
- Relative Strength Index (RSI)
- LPCN 39.07
- XAIR 38.57
- Support Level
- LPCN $2.86
- XAIR $2.12
- Resistance Level
- LPCN $3.00
- XAIR $2.38
- Average True Range (ATR)
- LPCN 0.12
- XAIR 0.13
- MACD
- LPCN -0.01
- XAIR 0.03
- Stochastic Oscillator
- LPCN 12.28
- XAIR 50.00
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.